Price Alert: Shares of Nuvation Bio (NUVB) Trade 10.35% Higher at Midday August 5

Equities Staff  |

Nuvation Bio Inc - Class A (NYSE: NUVB) has risen $0.239 (10.35%) and is currently sitting at $2.55, as of 12:01:36 est on August 5.

738,303 shares have been traded today.

The Company has decreased 20.47% over the last 5 days and shares have fallen 36.12% over the last 30 days.

Nuvation Bio is set to release earnings on 2022-08-09.

For technical charts, analysis, and more on Nuvation Bio visit the company profile.

About Nuvation Bio Inc - Class A

Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio's proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in New York and San Francisco.

To get more information on Nuvation Bio Inc - Class A and to follow the company's latest updates, you can visit the company's profile page here: Nuvation Bio Inc - Class A's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

China, Taiwan and the Boycott
An Easy Way to Profit Off One of Today’s Strongest Sectors
The Future of Smartphones is Still Unfolding: Jeff Kagan
These Stocks are Sending a Signal (Like Amazon in 2008)
It Isn’t a Recession Until This Group of Economists Says So
What You Should Know About Europe's Energy Wars
Meatless Meats and Smokeless Smokes
Mixed Wireless Recovery at AT&T, Verizon, T-Mobile: Jeff Kagan



Market Movers

Sponsored Financial Content